Investment Thesis
UTMD demonstrates fortress-like financial health with a 97% equity-financed balance sheet, exceptional 29.9% net margins, and $87.4M in cash, but faces material business headwinds with revenue declining 5.8% YoY and net income falling 18.7%. The critically low ROE of 2.2% and ROA of 2.1% indicate significant capital inefficiency despite strong profitability, suggesting excess idle capital without effective deployment or growth catalysts.
Strengths
- Fortress balance sheet: $120.4M equity, $4.0M liabilities, debt-free with $210K long-term debt
- Exceptional profitability margins: 60.6% gross, 29.4% operating, 29.9% net margin
- Outstanding cash generation: $3.0M FCF with 34.2% FCF margin; minimal $130K CapEx
- Extreme liquidity: 28.64x current ratio, 39.5x interest coverage ratio
Risks
- Revenue decline of 5.8% YoY indicates top-line business deterioration in medical device sector
- Net income dropped 18.7% YoY, faster than revenue decline, suggesting margin compression or operating deleveraging
- Critically low returns: ROE 2.2% and ROA 2.1% despite high margins indicates severe capital inefficiency with $87.4M underdeployed
- EPS declined 12.1% YoY; no insider buying activity to suggest management confidence
Key Metrics to Watch
- Revenue growth trajectory and stabilization; address the 5.8% YoY decline
- Return on Equity trend; 2.2% is untenable for a profitable company and suggests capital redeployment or M&A activity
- Operating margin sustainability; monitor for further compression below 29.4%
- Cash deployment strategy; clarify if $87.4M is strategic reserve or indicates business opportunity constraint
Financial Metrics
Revenue
8.7M
Net Income
2.6M
EPS (Diluted)
$0.82
Free Cash Flow
3.0M
Total Assets
124.4M
Cash
87.4M
Profitability Ratios
Gross Margin
60.6%
Operating Margin
29.4%
Net Margin
29.9%
ROE
2.2%
ROA
2.1%
FCF Margin
34.2%
Balance Sheet & Liquidity
Current Ratio
28.64x
Quick Ratio
26.15x
Debt/Equity
0.00x
Debt/Assets
3.2%
Interest Coverage
39.46x
Long-term Debt
210.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T07:07:38.184948 |
Data as of: 2026-03-31 |
Powered by Claude AI